Chemotherapy and local therapy for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a chemotherapy drug called nab-paclitaxel combined with other local treatments (like radiation) for people with small cell lung cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have small cell lung cancer that has spread beyond the lung where it started.
- You must have already had at least one previous treatment for your lung cancer.
- If you have brain metastases, they must be in the upper parts of the brain and causing no symptoms that need treatment.
- Your liver, kidney, and blood counts must be good enough (your doctor will check this with blood tests).
- You must not have had immunotherapy (like pembrolizumab or nivolumab) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.